An investigation has uncovered proof of serious misreporting, elevating new considerations in regards to the approval and long-term use of ticagrelor over the previous decade. In a follow-up investigation into the multibillion-dollar drug ticagrelor, The BMJ has recognized new considerations, this time specializing in key platelet research that supported the drug’s approval by the FDA. For over […]
Source link